Pfizer's ($PFE) bid to protect its pain drug Lyrica (pregabalin), which has lost some patent protection in the U.K., has had some unintended side effects. A recent court judgment--which said doctors must only prescribe the brand for neuropathic pain, an indication covered by a method patent--forced physicians to reissue prescriptions for the drug. The company has now apologized for "causing GPs concern" about the scripts, citing "discussion and media reporting" about the case. Report